Primer combination for detecting ATRX gene pathogenic mutation and use method of kit comprising primer combination

By introducing primer sets and kits for ATRX genes, combined with Sanger sequencing and gel electrophoresis detection, the problems of high cost and long cycle of detection of pathogenic mutations in the ATRX gene in the prior art have been solved, and rapid and economical detection results have been achieved .

CN118957056APending Publication Date: 2024-11-15SHENZHEN CITY BAOAN DISTRICT MATERNAL & CHILD HEALTH HOSPITAL

Patent Information

Application Number
CN202411309417.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-19
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing methods for detecting pathogenic mutations of the ATRX gene mainly rely on second-generation sequencing technology, which is costly and long-term, and lacks fast and economical detection kits.

Method used

A primer combination for detecting pathogenic mutations of the ATRX gene and a kit containing the primer set are proposed. The ATRX gene has pathogenic mutations, including the first primer set and the first primer set. The two primer set was used for PCR amplification and reverse transcription cDNA amplification, and was subjected to Sanger sequencing and gel electrophoresis detection, respectively.

Benefits of technology

It shortens the detection cycle, reduces the detection cost, and can quickly and economically detect ATRX gene pathogenic mutations under conventional biological laboratory conditions, which is suitable for rapid screening of clinical discovery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118957056A_ABST
    Figure CN118957056A_ABST
Patent Text Reader

Abstract

The invention discloses a primer combination for detecting ATRX gene pathogenic mutation and a use method of a kit containing the primer combination, and relates to the technical field of biology, the primer combination for detecting ATRX gene pathogenic mutation comprises a first primer group and a second primer group, the first primer group is used for detecting ATRX gene pathogenic mutation, the second primer group is used for detecting ATRX gene pathogenic mutation, and the second primer group is used for detecting ATRX gene pathogenic mutation. According to the technical scheme provided by the invention, the detection of ATRX gene pathogenic mutation can be completed by utilizing Sanger sequencing and gel electrophoresis detection, that is, whether the ATRX gene has pathogenic mutation or not can be determined through Sanger sequencing, so that the detection period is shortened, and the detection cost is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a primer combination for detecting pathogenic mutations of an ATRX gene and a method for using a kit comprising the primer combination. Background Art

[0002] The ATRX gene is located at Xq21.1, with a total length of 281kb. Its full name is "Alpha Thalassemia / Mental Retardation Syndrome X-linked". The ATRX gene is an important chromatin remodeling protein encoding gene, belonging to the SWI / SNF family. The protein it encodes plays a key role in regulating gene expression in cells, especially by depositing histone variant H3.3 at telomeres and other gene repeat sequences to maintain genome stability and proper gene expression. ATRX gene mutations are associated with a variety of diseases, the most famous of which is ATR-X syndrome, which includes α-thalassemia and intellectual disability. In addition, mutations in the ATRX gene have been found in a variety of cancers, such as gliomas and pancreatic neuroendocrine tumors, showing its importance in tumor suppression. From a molecular perspective, the ATRX protein interacts with multiple other proteins such as DAXX, which help assemble and modify chromatin, which is essential for cell replication and DNA damage repair processes.

[0003] In terms of genetics, ATR-X syndrome is an X-linked recessive genetic disease, usually affecting male hemizygotes, female homozygotes, and female compound heterozygous mutation individuals. Missense mutations, splicing mutations, small fragment deletions, and nonsense mutations may all cause the disease. Currently, there is no detection method for ATRX gene mutation sites. Generally, genetic etiology detection is performed through whole exome sequencing (WES) or whole genome sequencing (WES) technology. Both methods are second-generation sequencing technologies, which are expensive and have a long cycle. It is necessary to develop a rapid and economical detection kit for pathogenic mutations found in clinical practice. Summary of the invention

[0004] The main purpose of the present invention is to propose a primer combination for detecting pathogenic mutations in the ATRX gene and a method for using a kit containing the primer combination, aiming to determine whether the ATRX gene has a pathogenic mutation by Sanger sequencing and / or gel electrophoresis detection, thereby shortening the detection cycle and reducing the detection cost.

[0005] To achieve the above object, the present invention proposes a primer set for detecting pathogenic mutations in the ATRX gene, comprising a first primer set and a second primer set;

[0006] The first primer set includes a first upstream primer and a first downstream primer, the nucleotide sequence of the first upstream primer is shown in SEQ ID NO.1, and the nucleotide sequence of the first downstream primer is shown in SEQ ID NO.2;

[0007] The second primer set includes a second upstream primer and a second downstream primer, the nucleotide sequence of the second upstream primer is shown in SEQ ID NO.3, and the nucleotide sequence of the second downstream primer is shown in SEQ ID NO.4;

[0008] The present invention further proposes a method for using an ATRX gene detection kit, comprising the following steps:

[0009] A1. Performing PCR amplification on the extracted DNA using a first primer set, wherein the first primer set includes a first upstream primer and a first downstream primer, wherein the nucleotide sequence of the first upstream primer is shown in SEQ ID NO.1, and the nucleotide sequence of the first downstream primer is shown in SEQ ID NO.2;

[0010] A2. After the extracted mRNA is reverse transcribed to form cDNA, the formed cDNA is amplified by PCR using a second primer set, wherein the second primer set includes a second upstream primer and a second downstream primer, the nucleotide sequence of the second upstream primer is shown in SEQ ID NO.3, and the nucleotide sequence of the second downstream primer is shown in SEQ ID NO.4

[0011] A3, performing Sanger sequencing on the amplified product of the first primer set;

[0012] A4. Detect the amplified product of the second primer set by gel electrophoresis.

[0013] Optionally / in one embodiment, in the Sanger sequencing, the PCR reaction system includes the following components:

[0014] 10×PCR Buffer: 1.0 μL;

[0015] dNTP (2.5 mM): 0.8 μL;

[0016] MgCl2 (25 mM): 3.0 μL;

[0017] Upstream primer: 0.4 μL;

[0018] Downstream primer: 0.4 μL;

[0019] Genomic DNA (100 ng / μL): 1.0 μL;

[0020] Taq DNA polymerase: 0.1 μL;

[0021] ddH2O: 3.3 μL;

[0022] Total volume: 10 μL.

[0023] Optionally / in one embodiment, the amplification product size of the first primer set is 688 bp.

[0024] Optionally / in one embodiment, the thermal cycling conditions for the reverse transcription are: after extending the cDNA synthesis at 42°C for 15 minutes, the reverse transcriptase is extinguished at 70°C for 15 minutes.

[0025] Optionally / in one embodiment, the reverse transcription system comprises the following components:

[0026] mRNA: 8.0 μL;

[0027] Nuclease-Free Water: 0.6μL;

[0028] 5×Reaction Buffer: 4.0μL;

[0029] MgCl2 (25 mM): 4.0 μL;

[0030] Oligo(dT)15Primer(500μ / mL): 0.5μL;

[0031] Random Primers (500μ / mL): 0.5μL;

[0032] PCR Nucleotide Mix: 1.0μL;

[0033] Recombinant Ribonuclease Inhibitor: 0.4μL;

[0034] Reverse Transcriptase: 1.0μL;

[0035] Total volume: 20 μL.

[0036] Optionally / in one embodiment, the volumes of the components of the PCR amplification reaction system are as follows:

[0037] 10×PCR Buffer: 1.0 μL;

[0038] dNTP (2.5 mM): 0.8 μL;

[0039] MgCl2 (25 mM): 3.0 μL;

[0040] Upstream primer: 0.4 μL;

[0041] Downstream primer: 0.4 μL;

[0042] cDNA: 1.0 μL;

[0043] Taq DNA polymerase: 0.1 μL;

[0044] ddH2O: 3.3 μL;

[0045] Total volume: 10 μL.

[0046] Optionally / in one embodiment, the normal product of the second primer set is 535 bp, and the mutant product of the second primer set is 421 bp.

[0047] The present invention also provides a kit for detecting pathogenic mutations in the ATRX gene, comprising the above primer set

[0048] The present invention also proposes the use of the above kit in detecting pathogenic mutations of the ATRX gene.

[0049] The technical solution of the present invention adopts multiple sets of primer groups to detect the pathogenic mutation of the ATRX gene, so that the detection of the pathogenic mutation of the ATRX gene can be completed by Sanger sequencing and / or gel electrophoresis detection, that is, it can be determined whether the ATRX gene has a pathogenic mutation by Sanger sequencing and / or gel electrophoresis, thereby shortening the detection cycle and reducing the detection cost. BRIEF DESCRIPTION OF THE DRAWINGS

[0050] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the structures shown in these drawings without paying creative work.

[0051] Figure 1 This is a B-ultrasound image of the first embodiment of the present invention;

[0052] Figure 2 This is a schematic diagram of the Sanger sequencing results of Example 1;

[0053] Figure 3 This is a schematic diagram of gel electrophoresis detection in Example 1;

[0054] Figure 4 Schematic diagram of the principle of exon 6 being skipped due to mutation.

[0055] The realization of the purpose, functional features and advantages of the present invention will be further explained in conjunction with embodiments and with reference to the accompanying drawings. DETAILED DESCRIPTION

[0056] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0057] It should be noted that if the embodiments of the present invention involve directional indications (such as up, down, left, right, front, back, etc.), the directional indications are only used to explain the relative position relationship, movement status, etc. between the components in a certain specific posture. If the specific posture changes, the directional indication will also change accordingly.

[0058] In addition, if there are descriptions involving "first", "second", etc. in the embodiments of the present invention, the descriptions of "first", "second", etc. are only used for descriptive purposes and cannot be understood as indicating or implying their relative importance or implicitly indicating the number of technical features indicated. Therefore, the features limited to "first" and "second" may explicitly or implicitly include at least one of the features. In addition, if "and / or" or "and / or" appears in the full text, its meaning includes three parallel solutions. Taking "A and / or B" as an example, it includes solution A, solution B, or solutions that satisfy both A and B. In addition, the technical solutions between the various embodiments can be combined with each other, but it must be based on the ability of ordinary technicians in this field to implement. When the combination of technical solutions is contradictory or cannot be implemented, it should be deemed that such combination of technical solutions does not exist and is not within the scope of protection required by the present invention.

[0059] The ATRX gene is located at Xq21.1, with a total length of 281kb. Its full name is "AlphaThalassemia / MentalRetardationSyndromeX-linked". It is an important chromatin remodeling protein encoding gene and belongs to the SWI / SNF family. The protein encoded by this gene plays a key role in regulating gene expression in cells, especially by depositing histone variant H3.3 at telomeres and other gene repeat sequences to maintain genome stability and proper gene expression. ATRX gene mutations are associated with a variety of diseases, the most famous of which is ATR-X syndrome, which includes α-thalassemia and intellectual disability. In addition, mutations in the ATRX gene have been found in a variety of cancers, such as gliomas and pancreatic neuroendocrine tumors, showing its importance in tumor suppression. From a molecular perspective, the ATRX protein interacts with multiple other proteins such as DAXX, which help assemble and modify chromatin, which is essential for cell replication and DNA damage repair processes.

[0060] ATR-X syndrome (AlphaThalassemiaX-linkedIntellectualDisabilitySyndrome) is a rare genetic disease that mainly affects males and is usually caused by mutations in the ATRX gene on the X chromosome. The characteristics of this syndrome include intellectual disability, specific facial features, genitourinary abnormalities, and alpha-thalassemia. Alpha-thalassemia is a defect in hemoglobin production, but not all patients will show it. The clinical manifestations of ATR-X syndrome are very diverse, including developmental delay, low muscle tension, feeding difficulties, and delayed walking and language development. Many patients may not be able to walk independently or can only use limited vocabulary. Intellectual disability is the most significant clinical manifestation of ATR-X syndrome, but patients may also experience symptoms such as epileptic seizures and stiff leg movements. In addition, patients may show growth retardation, which may lead to short stature after puberty. In terms of facial features, patients with ATR-X syndrome usually have larger eye distance (exotropia), entropion, mid-face hypoplasia, flat nose, small triangular nose, etc. Many babies also have microcephaly (head circumference is smaller than normal for children of the same age), as well as low-set and posteriorly rotated ears. Prenatal imaging manifestations of fetuses with ATRX gene mutations are relatively rare in studies, with the most common manifestations being ventriculomegaly and white matter abnormalities.

[0061] In terms of genetics, ATR-X syndrome is an X-linked recessive genetic disease, usually affecting male hemizygous, female homozygous, and female compound heterozygous mutation individuals. Missense mutations, splicing mutations, small fragment deletions, and nonsense mutations may all cause the disease. Genetic etiology research on such patients, especially prenatal testing, will help improve the health of the newborn population.

[0062] Currently, there is no detection method for ATRX gene mutation sites. Genetic etiology detection is generally performed through whole exome sequencing (WES) or whole genome sequencing (WES) technology. Both methods are second-generation sequencing technologies, which are expensive and have a long cycle. It is necessary to develop a rapid and economical detection kit for pathogenic mutations found in clinical practice.

[0063] The present invention discovered a new classic splicing site mutation of ATRX, namely c.484+1G>A. There is no report of this mutation site in the ESP database, the Thousand People database, the EXAC database, the GnomAD database, etc. The wild-type ATRX gene is coded as ENSG00000085224 in the Ensemble database (https: / / useast.ensembl.org / index.html).

[0064] The present invention aims to provide a primer set, a kit and its use for rapid detection and verification of the ATRX gene c.484+1G>A mutation site. The alignment information of the ATRX gene c.484+1G>A mutation site and the human genome reference sequence GRCh37 is as follows:

[0065] The base G at the physical position 76949313 of chromosome X mutates to A, i.e., c.484+1G>A mutation, the first base of intron 6, i.e., the classic splice site mutation. This mutation will result in the lack of the entire exon 5 (114bp) in the mature mRNA. This mutation will cause the glycine (Gly) at position 124 to be converted to glutamic acid (Glu), and the deletion of positions 125-162, a total of 38 amino acids.

[0066] The present invention provides two sets of primers, which are respectively used to detect the pathogenic mutation sites of the ATRX gene found in clinical practice. Only conventional Sanger sequencing and / or PCR product gel electrophoresis are required to achieve the detection purpose. The technical requirements are very low, and the simplest biological laboratory has the detection conditions. The test results can be obtained quickly and at a low cost.

[0067] Specifically, the present invention proposes a primer set for detecting pathogenic mutations in the ATRX gene, comprising a first primer set and a second primer set;

[0068] The first primer set includes a first upstream primer and a first downstream primer, the nucleotide sequence of the first upstream primer is shown in SEQ ID NO.1, and the nucleotide sequence of the first downstream primer is shown in SEQ ID NO.2;

[0069] The second primer set includes a second upstream primer and a second downstream primer. The nucleotide sequence of the second upstream primer is shown in SEQ ID NO.3, and the nucleotide sequence of the second downstream primer is shown in SEQ ID NO.4.

[0070] In the present invention, the primer sequences in each primer set are shown in the following table:

[0071] Table 1 Sequence list of primers in the primer set

[0072]

[0073] It should be noted that, in the present invention, the first primer set is used for Sanger sequencing, and the second primer set is used for gel electrophoresis detection.

[0074] Among the two primer sets provided in the present invention, the specific process for the first primer set in Sanger sequencing is as follows:

[0075] 1. Draw peripheral blood from the subject in an EDTA anticoagulant tube and extract genomic DNA;

[0076] 2. Prepare the PCR reaction system. The PCR reaction system is shown in the following table:

[0077] Table 2 Sanger sequencing PCR reaction system

[0078] Components Volume (μL) 10×PCR Buffer 1.0 dNTP(2.5mM) 0.8 <![CDATA[MgCl2(25mM)]]> 3.0 Upstream primer 0.4 Downstream primer 0.4 Genomic DNA (100 ng / μL) 1.0 Taq DNA polymerase 0.1 <![CDATA[ddH2O]]> 3.3 Total volume 10

[0079] 3. Perform PCR amplification in a thermal cycler under the following conditions. The amplification program is shown in the following table:

[0080] Table 3 PCR amplification program

[0081]

[0082]

[0083] The PCR product is directly subjected to conventional Sanger sequencing. The sequencing primers are the same as the PCR primers, and the result can be directly judged based on the sequencing results.

[0084] Among them, the size of the amplified product of the first primer set is as follows:

[0085] Table 4 Size of the amplified product of the first primer set

[0086]

[0087] Among the two primer sets provided in the present invention, the second primer set can detect the splicing mutation of exon 6, and the specific process for use in gel electrophoresis detection is as follows:

[0088] 1. Draw peripheral blood from the subject in an EDTA anticoagulant tube and extract mRNA;

[0089] 2. Prepare the reverse transcription system as follows:

[0090] Table 5 Reverse transcription system

[0091]

[0092]

[0093] 3. The reverse transcription thermal cycle conditions were: 42°C, 15 min extension to synthesize cDNA, 70°C, 15 min reverse transcriptase quenching;

[0094] 4. Using the cDNA synthesized in the previous step as a template, use the second primer set to configure the PCR reaction system. The specific reaction system is shown in the following table:

[0095] Table 6 PCR reaction system of the second primer set

[0096] Components Volume (μL) 10×PCR Buffer 1.0 dNTP(2.5mM) 0.8 <![CDATA[MgCl2(25mM)]]> 3.0 Upstream primer 0.4 Downstream primer 0.4 cDNA 1.0 Taq DNA polymerase 0.1 <![CDATA[ddH2O]]> 3.3 Total volume 10

[0097] 5. Perform PCR amplification in a thermal cycler under the following conditions. The amplification program is shown in the following table:

[0098] Table 7 PCR amplification program of the second primer set

[0099] Temperature(℃) time Number of cycles 95 3 minutes 1 95 15 seconds 34 62 15 seconds 34 72 30 seconds 34 72 5 minutes 1 4 ∞ 1

[0100] The amplified product was subjected to gel electrophoresis and the size of the bands could be used to determine whether the product was 535 bp or a normal ATRX gene. If a 421 bp product was also produced, it indicated that the entire exon 6 was skipped due to a splicing site mutation.

[0101] It should be noted that the above-mentioned Sanger sequencing and the above-mentioned gel electrophoresis detection can be performed separately, that is, the above-mentioned Sanger sequencing and the above-mentioned gel electrophoresis detection can both detect the mutation of the ATRX gene separately; the two can also be performed on the same sample at the same time to compare the results with each other and reduce the probability of false detection.

[0102] The following is described in conjunction with specific embodiments:

[0103] Example 1

[0104] A non-consanguineous couple denied family history of genetic diseases. The pregnant woman was giving birth for the second time and the previous baby had a normal phenotype. Figure 1 The second child had an enlarged left ventricle of 1.41 cm on prenatal ultrasound at 26 weeks of gestation, and a fetal cranial MRI diagnosed an enlarged left ventricle of 1.52 cm.

[0105] Amniotic fluid prenatal diagnosis of CMA + CMV showed no abnormalities. Figure 2 , verified by the primer set of the present invention, the fetus has the ATRX gene c.484+1G>A mutation, and neither of its parents carries this mutation, which is a new mutation in the fetus.

[0106] The second primer set was used to perform PCR amplification on the cDNA of normal people and the fetus. After electrophoresis analysis, the amplified fragment of normal people was 535bp, while the amplified fragment of the proband was 421bp. After sequencing, due to the mutation of the splicing site, the entire 114bp of exon 6 was missing in the mature mRNA, and only a segment of ATRX protein lacking 38 amino acids could be synthesized, thus causing the disease. Figure 3 and Figure 4 After sequencing, the large and small fragments in the above gel electrophoresis were consistent with the theoretical sequence, that is, the difference of the small fragment was that exon 6 was skipped.

[0107] The present invention also proposes a kit for detecting pathogenic mutations in the ATRX gene, which includes the above-mentioned primer set. The specific sequence and usage of the primer set refer to the above description and embodiments. Since the present kit adopts all the technical solutions of all the above-mentioned embodiments, it has at least all the beneficial effects brought by the technical solutions of the above-mentioned embodiments, which will not be repeated here one by one.

[0108] The present invention also proposes the use of the above-mentioned kit in detecting pathogenic mutations of the ATRX gene. The above-mentioned kit can be used as one of the means for rapid screening of pathogenic mutations of the ATRX gene; and because the present invention uses Sanger sequencing and gel electrophoresis detection, the experimental conditions are very low and can be used in conventional biological laboratories. The cost is very low and the detection cycle is short.

[0109] The above description is only an exemplary embodiment of the present invention, and does not limit the patent scope of the present invention. All equivalent structural changes made by using the contents of the present invention specification and drawings under the technical concept of the present invention, or directly / indirectly applied in other related technical fields are included in the patent protection scope of the present invention.

Claims

1. A primer set for detecting pathogenic mutations in the ATRX gene, characterized in that: comprising a first primer set and a second primer set; The first primer set includes a first upstream primer and a first downstream primer, the nucleotide sequence of the first upstream primer is shown in SEQ ID NO.1, and the nucleotide sequence of the first downstream primer is shown in SEQ ID NO.2; The second primer set includes a second upstream primer and a second downstream primer. The nucleotide sequence of the second upstream primer is shown in SEQ ID NO.3, and the nucleotide sequence of the second downstream primer is shown in SEQ ID NO.

4.

2. A method for using an ATRX gene detection kit, comprising the following steps: A1. Performing PCR amplification on the extracted DNA using a first primer set, wherein the first primer set includes a first upstream primer and a first downstream primer, wherein the nucleotide sequence of the first upstream primer is shown in SEQ ID NO.1, and the nucleotide sequence of the first downstream primer is shown in SEQ ID NO.2; A2, after reverse transcribing the extracted mRNA to form cDNA, a second primer set is used to perform PCR amplification on the formed cDNA, wherein the second primer set includes a second upstream primer and a second downstream primer, the nucleotide sequence of the second upstream primer is shown in SEQ ID NO.3, and the nucleotide sequence of the second downstream primer is shown in SEQ ID NO.4; A3, performing Sanger sequencing on the amplified product of the first primer set; A4. Detect the amplified product of the second primer set by gel electrophoresis.

3. The method for using the kit according to claim 2, characterized in that: In the Sanger sequencing, the PCR reaction system includes the following components: 10×PCR Buffer: 1.0 μL; dNTP (2.5 mM): 0.8 μL; MgCl2 (25 mM): 3.0 μL; Upstream primer: 0.4 μL; Downstream primer: 0.4 μL; Genomic DNA (100 ng / μL): 1.0 μL; Taq DNA polymerase: 0.1 μL; ddH2O: 3.3 μL; Total volume: 10 μL.

4. The method for using the kit according to any one of claims 2 to 3, characterized in that: The size of the amplified product of the first primer set is 688 bp.

5. The method for using the kit according to claim 2, characterized in that: The thermal cycle conditions of the reverse transcription were as follows: after extending and synthesizing cDNA at 42° C. for 15 min, the reverse transcriptase was quenched at 70° C. for 15 min.

6. The method for using the kit according to claim 5, characterized in that: The reverse transcription system comprises the following components: mRNA: 8.0 μL; Nuclease-Free Water: 0.6μL; 5×Reaction Buffer: 4.0μL; MgCl2 (25 mM): 4.0 μL; Oligo(dT) 15 Primer(500μ / mL):0.5μL; Random Primers (500μ / mL): 0.5μL; PCR Nucleotide Mix: 1.0μL; Recombinant Ribonuclease Inhibitor: 0.4μL; Reverse Transcriptase: 1.0μL; Total volume: 20 μL.

7. The method for using the kit according to claim 6, characterized in that: The volumes of the components of the PCR amplification reaction system are as follows: 10×PCR Buffer: 1.0 μL; dNTP (2.5 mM): 0.8 μL; MgCl2 (25 mM): 3.0 μL; Upstream primer: 0.4 μL; Downstream primer: 0.4 μL; cDNA: 1.0 μL; Taq DNA polymerase: 0.1 μL; ddH2O: 3.3 μL; Total volume: 10 μL.

8. The method for using the kit according to any one of claims 5 to 7, characterized in that: The normal product of the second primer set is 535 bp, and the mutant product of the second primer set is 421 bp.

9. A kit for detecting pathogenic mutations in the ATRX gene, characterized in that: Comprising the primer set according to any one of claims 1 to 8.

10. Use of the kit according to claim 9 in detecting pathogenic mutations in the ATRX gene.

Citation Information

Patent Citations

  • Methods and compositions for treatment of cancer and autoimmune disease

    CN103765212A

  • Mutation site of intellectual disability disease-related ATRX gene and detection kit

    CN113151445A

Cited By

  • Peripheral neuroblastoma ATRX gene deletion detection primer group, kit and application of peripheral neuroblastoma ATRX gene deletion detection primer group

    CN121182957A